ONKION - Key Persons

Job Titles:

• Guillarmod, Legal Counsel, Switzerland

Job Titles:

• Chief Business Officer and Acting Co - CSO

Dimitri was educated in the U.K. with a degree in Chemistry and Biochemistry, and a Ph.D. in Molecular Biology (Immunology) from the University of Oxford. He became Project Director, based in Basel, and was in charge of development projects in a number of therapeutic areas, incl. Metabolism, Cardiovascular and CNS. In 1998 he joined The Medicines Company (MDCO) in Basel, as Project Director. Following the listing (IPO) of MDCO on the NASDAQ (Aug 2000), he joined another start-up company in Basel, Speedel. He was the first full-time employee of Speedel, and played a key role in the development of the company for over 6 years, incl. its listing on the Zurich Stock Exchange (Sep 2005). He was promoted to Managing Director of Speedel Experimenta. Dimitri was asked to re-join The Medicines Company (MDCO) in Jan 2009. In Jan 2010 he became Global Head of Research and Development (R&D) of MDCO, and for that role he moved from Germany to the US (New Jersey). He re-engineered the R&D department, ca. 150 employees and annual budget of $120 mio, and met every single financial and development target set by the Board each year and each quarter. He was promoted to Senior Vice President of MDCO in 2011. Dimitri has published over 20 scientific articles, including Nature and is co-inventor of a patent (both US & EU) on the potential therapeutic uses of the properdin and thrombospondin units. He has been CEO of MaxiVax SA an Immuno-Oncology Biotechnology company with headquarters in Geneva until 2021.

Job Titles:

• Member of the Scientific Advisory Board
• Austria

Franz is qualified by training in Chemistry and in Biochemistry at doctorate level from the University of Vienna. His career started as post-doctoral fellow and then laboratory leader at Sandoz Pharma. Subsequently he moved as laboratory head at the Novartis institute of Biomedical research and then he became laboratory head in Biology I for Novartis Institute at Horsham (UK). In 2008 he founded NBS-C a specialized boutique provider for R&D laboratory services focused in ligand-target interactions. He has extensive experience in the broad protein chemistry arena with emphasis in monoclonal antibody characterization and interaction with target. He has co-authored more than 50 peer-reviewed publications and he is inventor in 11 granted patents. Franz is a member of key scientific societies and in the board of scientific journals.

Job Titles:

• Member of the Management Team
• ( Oxon ), FRCPath., Managing Director and Acting CSO

Qualified in Medicine, in General Medical Council's (UK) specialist's register. Doctor of Philosophy in Biochemistry & Molecular Biology (D.Phil., University of Oxford, UK). He has served in various positions within the Academia, such as Group Leader at the Department of Pathology, Duke University Medical Center, NC, USA as senior Investigator at the German Cancer Research Centre (DKFZ, Heidelberg) & senior Lecturer at University College London, (UK) for more than 20 years. He is advising on R&D science and strategy Biotech players in the EU and the USA. Since 2002 he has continued in various pre-clinical R&D and medical director positions in Pharmaceutical companies to include Eli Lilly (Oncology), Roche Products Ltd. (Oncology & Hepatitis), Daiichi Sankyo Inc. (Neuropathic Pain) and GSK (Immunology & Oncology), Astellas (Oncology). He has co-authored about 40 peer-reviewed publications, edited 3 books, mostly in the signal transduction and receptor-ligand interactions arena and he is inventor in 5 patents.

Job Titles:

• Chief Financial Officer

Lukas has a valuable experience encompassing a number of sectors and across different activities. He has been with Akompani SA Switzerland till 2018. Akompani SA provides strategic business advisory and M&A services including investments, divestments and financing for SMEs across multiple sectors. His key capabilities as senior advisor include business and shareholder strategy, organization and governance, restructuring, operational excellence and digital transformation. M&A (Sell- and Buy Side), business successions, MBO/MBI and merger advisory. Financial advisory, scenario building & analysis, growth financing and fund raising. His next assignment was with H.GLASS SA in Switzerland, a renewable technology provider engaged in the development, production and commercialization of transparent, organic solar cells with a share capital of CHF 23.5m and 50 employees. Portfolio company of Swisscom (SCMN.VX). As CFO, Finance & Business Operations: Lukas was responsible for finance and business operations, member of the executive management team. He was responsible for Financial management and investments and accounting operations. Led the company's general financial planning processes, controlling and coordination of business plans, budgets and forecasts. Also, responsible for investor relations and corporate secretary activities (general assembly, share transfers, capital increases, shareholder loans.

Job Titles:

• Member of the Scientific Advisory Board

Since thirty years Dr. Arcangeli is being involved in studies aimed at defining the biophysical aspects of intracellular signaling controlling cell growth and differentiation of tumor cells. She contributed to unravel the action mechanism of widely used inducers of tumor cell differentiation, such as the "hybrid polar compounds" (HPC). She also focused on the role of potassium channels, in particular the hERG1 channel, in the govern of the resting potential, cellular ionic homeostasis and cell signaling in normal and cancer cells. In this field, Dr. Arcangeli acquired most of the methodologies required to accomplish the present proposal, in particular gene manipulation, biomolecular techniques and patch clamping. Meanwhile, in the last few years she exploited her skill in mouse transgenesis and in vivo experiments in immunodeficient mice. These studies led to discovery that, in many human and experimental tumors, the resting potential is controlled by hERG1, an important family of recently discovered potassium channels. Moreover, Dr. Arcangeli integrating biophysical, biomolecular and genetic approaches unravelled the role of potassium channels and their encoding genes, in embryonic development and tumor establishment. She is a member of Italian and international scientific organizations and has co-authored into more than 200 publications in peer-reviewed journals.

Job Titles:

• Member of the Scientific Advisory Board
• Head of the Lymphoma Genomics Group at Institute of Oncology Research
• Switzerland )

Prof. Francesco Bertoni is the head of the Lymphoma Genomics group at Institute of Oncology Research in Bellinzona, Switzerland, the Institute deputy director, and Adjunct Professor at the Faculty of Biomedical Sciences, USI. His research topics are the development of new anti-lymphoma compounds and lymphoma genomics. During his career he has worked in Milan (Ospedale Maggiore Policlinico and "Mario Negri" Institute of Pharmacological Research), London (Institute of Child Health and The Barts and The London) and in Ticino (Servizio Oncologico Cantonale). Since April 2003, he has been leading his group in Bellinzona. Bertoni actively participates to Swiss Cancer Research Group (SAKK), in which he is President of the Project Group Lymphoma and member of the Project Group Developmental Therapeutics. He is Editor-in-Chief of Hematological Oncology journal since 2008, and President of the Local Organizing Committee of the International Conference on Malignant Lymphoma (ICML). Prof Bertoni is the author or co-author of over 200 original papers, over 50 editorials or invited reviews, 20 book sections, over 10 patents, one edited book and several abstracts at national and international meetings.

Job Titles:

• Member of the Scientific Advisory Board
• Senior Associate

Dr. Zamponi is Senior Associate Dean for Research and Full Professor in the Cumming School of Medicine at the University of Calgary where he commenced his faculty position. He previously served as the Head of the Department of Physiology and Pharmacology. He received his undergraduate training in Engineering Physics from the Johannes Kepler University in Austria, followed by a PhD in Neuroscience at the University of Calgary and postdoctoral work at the University of British Columbia in Canada. Dr. Zamponi's research addresses how ion channels and receptors contribute to neurological disorders such as chronic pain, with the goal of developing strategies to regulate ion channel function for therapeutic intervention. His work also deciphers the functional connectomics of brain circuits that process pain signals. The translational impact of his work is evident from his co-founding of NeuroMed Pharmaceuticals and Zymedyne Therapeutics, and inventorship on 12 issued US patents pertaining to new pain therapeutics. He has published over 320 articles, has given more than 250 invited lectures across the globe and has attracted in excess of $25 Million in research support to his lab. Dr. Zamponi is the recipient of numerous prestigious awards. In addition to having been an Alberta Innovates-Health Solutions Scientist and Canadian Institutes of Health Research Investigator, he is currently a Canada Research Chair in Molecular Neurobiology. He is an elected Fellow of both the Royal Society of Canada, and the Canadian Academy of Health Sciences, which represents top honors for those in the basic and medical science, respectively.

Job Titles:

• Member of the Scientific Advisory Board
• Board Member of Aalborg University

Professor Nielsen is a Board member of Aalborg University in Denmark. He is the founder of a clinical trial centre C4Pain (www.C4Pain.com) devoted to phase Ib, II, and III experimental and clinical pain studies utilizing the most advanced translational pain bio-markers and pain assessment tools. Prof. Nielsen has published more than 1,050 peer reviewed journal papers (sum of times cited 24,897, average citations per item 27.06, H-index 73, Web of Science) in the broad area of Ion Channels, motor control and profiling of analgesic and anti-inflammatory compounds. He has edited six books and has been guest editor for two international journals. Editorial board member of 5 international journals and regular reviewer for 20 international journals. He is also recipient of nearly 20 national and international honors and awards.

Job Titles:

• Member of the Management Team
• Non - Executive Director

Tatiana is serving as non-executive director representing Onkion SA on Pharmixon's board. Tatiana by training has a B.Sc. and a Master's degrees in humanities and a doctorate in philosophy. In addition, she is trained in international taxation at Master's level and has worked and offered her services to a number of corporate ventures to include Doltec SA (Montreux), Rossmills group (Montreux), T&CO law firm (Switzerland) and she is co-founder of global IP solutions (Switzerland). Her support for Pharmixon is focused in areas linked to corporate governance and compliance, international accountancy and fiscal standard compliance as well as in business development.

Job Titles:

• Legal Counsel

Taylor Wessing is a legal firm headquartered in London, UK with solid expertise in transactions linked to Life sciences/Biotechnology/Pharmaceuticals. We have been working with partners of Taylor Wessing on a number of themes related to company's IP strategy, licensing agreements as well as deal negotiating strategies for the purpose of fundraising.